Back to Browse Journals » International Journal of Nanomedicine » Volume 6

Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs) in vivo

Authors Tang QS, Chen DZ, Xue WQ, Xiang JY, Gong YC, Zhang L, Guo CQ

Published Date November 2011 Volume 2011:6 Pages 3077—3085

DOI http://dx.doi.org/10.2147/IJN.S24322

Published 30 November 2011

Qiu-Sha Tang1,*, Dao-Zhen Chen2,*, Wen-Qun Xue2, Jing-Ying Xiang2, Yong-Chi Gong1, Li Zhang2, Cai-Qin Guo2
1Department of Pathology and Pathophysiology, Medical College, Southeast University, Nanjing, Jiangsu; 2Central Laboratory, Wuxi Hospital for Maternal and Child Health Care, Affiliated Medical School of Nanjin, Wuxi, Jiangsu, China
*Authors contributed equally to this work

Background: The purpose of this study was to develop intraperitoneal hyperthermic therapy based on magnetic fluid hyperthermia, nanoparticle-wrapped cisplatin chemotherapy, and magnetic particles of albumin. In addition, to combine the multiple-killing effects of hyperthermal targeting therapy, chemotherapy, and radiotherapy, the albumin-nanoparticle surfaces were linked with radionuclide 188Re-labeled folic acid ligand (188Re-folate-CDDP/HSA).
Methods: Human serum albumin was labeled with 188Re using the pre-tin method. Reaction time and optimal conditions of labeling were investigated. The particles were intravenously injected into mice, which were sacrificed at different time points. Radioactivity per gram of tissue of percent injected dose (% ID/g) was measured in vital organs. The biodistribution of 188Re-folate-CDDP/HAS magnetic nanoparticles was assessed.
Results: Optimal conditions for 188Re-labeled folate-conjugated albumin combined with cisplatin magnetic nanoparticles were: 0.1 mL of sodium gluconate solution (0.3 mol/L), 0.1 mL of concentrated hydrochloric acid with dissolved stannous chloride (10 mg/mL), 0.04 mL of acetic acid buffer solution (pH 5, 0.2 mol/L), 30 mg of folate-conjugated albumin combined with cisplatin magnetic nanoparticles, and 188ReO4 eluent (0.1 mL). The rate of 188Re-folate-CDDP-HSA magnetic nanoparticle formation exceeded 90%, and radiochemical purity exceeded 95%. The overall labeling rate was 83% in calf serum at 37°C. The major uptake tissues were the liver, kidney, intestine, and tumor after the 188Re-folate-CDDP/HSA magnetic nanoparticles were injected into nude mice. Uptake of 188Re-folate-CDDP/HSA magnetic nanoparticles increased gradually after injection, peaked at 8 hours with a value of 8.83 ± 1.71, and slowly decreased over 24 hours in vivo.
Conclusion: These results indicate that 188Re-folate-CDDP/HSA magnetic nanoparticles can be used in radionuclide-targeted cancer therapy. Surface-modified albumin nanoparticles with folic acid ligand-labeled radionuclide (188Re) were successfully prepared, laying the foundation for a triple-killing effect of thermotherapy, chemotherapy, and radiation therapy.

Keywords: cisplatin, folic acid, albumin, magnetic nanoparticles, 188Re, ovarian cancer

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells

Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ

International Journal of Nanomedicine 2012, 7:4973-4982

Published Date: 14 September 2012

Readers of this article also read:

Magnetic particle imaging: kinetics of the intravascular signal in vivo

Haegele J, Duschka RL, Graeser M, Schaecke C, Panagiotopoulos N, L├╝dtke-Buzug K, Buzug TM, Barkhausen J, Vogt FM

International Journal of Nanomedicine 2014, 9:4203-4209

Published Date: 3 September 2014

The epidemiology of eating disorders: genetic, environmental, and societal factors

Mitchison D, Hay PJ

Clinical Epidemiology 2014, 6:89-97

Published Date: 17 February 2014

Evaluation of glycophenotype in breast cancer by quantum dot-lectin histochemistry

Andrade CG, Cabral Filho PE, Tenorio DPL, Santos BS, Beltrão EIC, Fontes A, Carvalho Jr LB

International Journal of Nanomedicine 2013, 8:4623-4629

Published Date: 2 December 2013

Nanosized sustained-release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics

Tan Q, Jiang R, Xu M, Liu G, Li S, Zhang J

International Journal of Nanomedicine 2013, 8:737-745

Published Date: 20 February 2013

An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma

Shen M, Gong FM, Pang PF, Zhu KS, Meng XC, Wu C, Wang J, Shan H, Shuai XT

International Journal of Nanomedicine 2012, 7:3319-3332

Published Date: 2 July 2012

Servant leadership: a case study of a Canadian health care innovator

Vanderpyl TH

Journal of Healthcare Leadership 2012, 4:9-16

Published Date: 16 February 2012